Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, at least 18 years of age.
Patients with compensated chronic hepatitis B who are currently receiving adefovir 10mg once daily.
Patients must have received adefovir 10mg once daily for at least 48 weeks continuously and have a sub-optimal response to adefovir therapy (≥4log10 copies of HBV DNA/mL).
Patient is willing to comply with all study requirements.
Patient is willing and able to provide written informed consent.
You may not be if
Pregnant or nursing (lactating) women. All women must have a negative pregnancy test at the screening visit.
Female patients of reproductive potential is unwilling to use double barrier method of contraception (condom plus spermicide or diaphragm plus spermicide).
Patient is co-infected with hepatitis C virus or HIV.
Patient has previously taken lamivudine.
Patient is currently abusing illicit drugs or alcohol.
Patient is using any investigational drugs or with in the last 30 days.
Patient is enrolled or plans to enroll in a clinical study involving investigational drug.
Patient has a history of pancreatitis, hepatic decompsensation, Hepatocellular Carcinoma, or a history of hypersensitivity to telbivudine or adfovir.
Clareo Health | Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B
